Non-sedating dexmedetomidine treatment regimens
US11998529B2 · kind B2 · utility
0Cited by
155References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2023 |
| Grant date | Jun 4, 2024 |
| Priority date | — |
| Expiry date | Jun 30, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/36
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.